630 related articles for article (PubMed ID: 7932398)
41. [Alternative to bromocriptine (BEC) management in patients with prolactinoma and intolerance to oral BEC].
Fletes Rabago VM; Torres Farias S; Domínguez Jiménez A; Padilla Ruiz R
Ginecol Obstet Mex; 1991 Sep; 59():283-8. PubMed ID: 1797615
[TBL] [Abstract][Full Text] [Related]
42. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
43. [The treatment of prolactinoma].
Serri O; Somma M; Beauregard H; Rasio E; Comtois R; Aris-Jilwan N; Boucher A; Hardy J
Union Med Can; 1993; 122(6):496-9. PubMed ID: 7905686
[TBL] [Abstract][Full Text] [Related]
44. Treatment of macroprolactinomas at Auckland Hospital 1975-91.
Wallace EA; Holdaway IM
N Z Med J; 1995 Feb; 108(994):50-2. PubMed ID: 7885646
[TBL] [Abstract][Full Text] [Related]
45. The use of surgery for the treatment of prolactinomas.
van't Verlaat JW
Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():34-7. PubMed ID: 8103958
[TBL] [Abstract][Full Text] [Related]
46. Medical therapy of prolactinomas.
Jaquet P
Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():31-3. PubMed ID: 8103957
[TBL] [Abstract][Full Text] [Related]
47. [Role of hypothalamo-hypophyseal-adrenal axis in the pathogenesis of arterial hypertension in patients with prolactinoma of the anterior lobe of the hypophysis].
Mychka VB; Chazova IE; Dmitriev VV; Masenko VP
Ter Arkh; 2000; 72(9):10-3. PubMed ID: 11076407
[TBL] [Abstract][Full Text] [Related]
48. [Treatment of macroprolactinomas with quinagolide (Norprolac)].
Tabarin A; Catargi B
Ann Endocrinol (Paris); 1997; 58(2):87-94. PubMed ID: 9239226
[TBL] [Abstract][Full Text] [Related]
49. [Bromocriptine for macroprolactinomas. Discussion of 3 cases treated successfully].
Sapunar J; López JM; Huete I; Tagle R
Rev Med Chil; 1992 Feb; 120(2):168-73. PubMed ID: 1340555
[TBL] [Abstract][Full Text] [Related]
50. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
Brue T; Pellegrini I; Gunz G; Morange I; Dewailly D; Brownell J; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
[TBL] [Abstract][Full Text] [Related]
51. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
[TBL] [Abstract][Full Text] [Related]
52. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.
Ciccarelli E; Miola C; Grottoli S; Avataneo T; Lancranjan I; Camanni F
J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794
[TBL] [Abstract][Full Text] [Related]
53. Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: a novel approach to intolerance of oral therapy.
Katz E; Schran HF; Adashi EY
Obstet Gynecol; 1989 Mar; 73(3 Pt 2):517-20. PubMed ID: 2915884
[TBL] [Abstract][Full Text] [Related]
54. [Prolactin microadenoma in men. Study of 14 cases].
Gimenez-Roqueplo AP; Dupuy M; Delalande O; Visot A; Jedynak CP; Peillon F; Derome PJ
Ann Med Interne (Paris); 1992; 143(2):94-7. PubMed ID: 1530227
[TBL] [Abstract][Full Text] [Related]
55. Large macroprolactinoma treated with bromocriptine alone.
Loh KC; Shlossberg AH
Ann Acad Med Singap; 1996 Nov; 25(6):886-9. PubMed ID: 9055023
[TBL] [Abstract][Full Text] [Related]
56. Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy.
Bronstein MD
Nat Clin Pract Endocrinol Metab; 2006 Mar; 2(3):130-1. PubMed ID: 16932269
[No Abstract] [Full Text] [Related]
57. Long term treatment with CV 205-502 in patients with prolactin-secreting pituitary macroadenomas.
Serri O; Beauregard H; Lesage J; Pedneault L; Comtois R; Jilwan N; Somma M; Vachon L; Brownell J
J Clin Endocrinol Metab; 1990 Sep; 71(3):682-7. PubMed ID: 2394774
[TBL] [Abstract][Full Text] [Related]
58. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
Eroukhmanoff J; Tejedor I; Potorac I; Cuny T; Bonneville JF; Dufour H; Weryha G; Beckers A; Touraine P; Brue T; Castinetti F
Eur J Endocrinol; 2017 Mar; 176(3):323-328. PubMed ID: 28073906
[TBL] [Abstract][Full Text] [Related]
59. Current treatment issues in female hyperprolactinaemia.
Crosignani PG
Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):152-64. PubMed ID: 16288952
[TBL] [Abstract][Full Text] [Related]
60. Dopaminergic effects on kidney function and responsiveness of aldosterone, plasma renin activity, prolactin, catecholamines, and blood pressure to stimulation in patients with prolactinoma. Comparison of the efficacy of pergolide and bromocriptine therapy.
Jungmann E; Haak T; Althoff PH; Fassbinder W; Schöffling K
Arzneimittelforschung; 1988 Feb; 38(2):296-300. PubMed ID: 3285838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
